BioSpace News Archive

Kala Pharmaceuticals, Inc. today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.

Stereotaxis announces that BJC HealthCare has become the first health care system in the midwest to offer the Genesis RMN system, advancing electrophysiology patient care and expanding access to advanced robotic technology for the treatment of cardiac arrhythmias in the greater St. Louis region.

Revelation Biosciences Inc. (Revelation), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, announced today the initiation for its Phase 1b proof-of-concept nasal allergen challenge clinical study (RVL-CLR01) to evaluate the potential utility of REVTx-99 for treating patients with allergic rhinitis and patients with chronic nasal congestion without polyps.

Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, announced the presentation of new data from its αvβ8 integrin inhibition program at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting.

AnaptysBio, Inc. (Nasdaq: ANAB), today announced positive top-line data from a randomized placebo-controlled healthy volunteer single and multiple ascending dose Phase 1 trial of rosnilimab, its investigational wholly-owned anti-PD-1 agonist therapeutic antibody, previously known as ANB030.

Bluesail Medical Co., Ltd, a leading medical device enterprise with the complete layout of low,medium and high value consumables, has launched its new series of innovative products on November 15 at MEDICA 2021 in Dusseldorf, a world-leading medical exhibition in Germany.

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), today announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) eligibility to CT041, an autologous CAR T-cell product candidate against the claudin18.2 protein (CLDN18.2) for the treatment of gastric/gastroesophageal junction cancer (GC/GEJ).

Moderna Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today confirmed that Health Canada authorized the use of a booster dose of the Moderna COVID-19 vaccine (SPIKEVAX™) at the 50 µg dose for individuals aged 18 and older administered at least six months after completion of the primary series.

CYduct Diagnostics, Inc. is pleased to announce the retaining of Ms. Laura Anthony and the firm Anthony L.G., PLLC.

Today, Thimble Point Acquisition Corp, Inc. and Pear Therapeutics, Inc. jointly announced an additional commitment from an affiliate of Thimble Point’s sponsor of up to $50 million.